CTRI/2021/05/033813尚未招募未知
TWO YEAR FOLLOW UP STUDY ON POSTOPERATIVE CASES OF HEPATICOJEJUNOSTOMY DONE FOR BENIGN BILIARY DISEASES WITH FOCUS ON THE FACTORS LEADING TO EARLY RECURRENCE OF BILIARY STRICTURE
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients who had undergone hepatico-jejunostomy for management of benign biliary diseases and willing to give written informed consent and follow study procedure.
排除标准
- •1.Patients who had undergone hepatico-jejunostomy for management of malignant causes or liver transplantation.
- •2.Patients who didnot give written informed consent to follow study procedure.
研究者
相似试验
进行中（未招募）
1 期
Extension study for the follow up of patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulated and blinded controlled treatment to evaluate safety and efficacy of a drug administered (etamsilato) via a needle in the eye. Clinical trial code OFT-ETAMSILATO -4.2.1EUCTR2015-001812-36-ESDr. Pedro Cuevas Sanchez (Investigacion Independiente)44
已完成
不适用
A two year clinical follow up of the single visit crown, comparing two different placement techniquesISRCTN17542282ewcastle upon Tyne Hospitals Trust20
招募中
1 期
ong-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Kidney Transplant RejectionMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613CTIS2024-512580-31-00Sangamo Therapeutics France30
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15